Effect of Clopidogrel on Midterm Graft Patency following Off-Pump Coronary Revascularization Surgery
Objective. The aim of the study was to evaluate the effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery.
Design. Ninety-four consecutive patients who underwent off-pump coronary artery bypass grafting between 1997 and 2002 were studied (58 men, 36 women; 61.7 ± 9.8 years). The initial 36 patients (control group) received 75 to 160 mg acetyl salicylic acid (ASA) as an antiplatelet agent, whereas the consecutive 58 patients (clopidogrel group) received 75 mg clopidogrel postoperatively in addition to ASA. Intraoperatively, graft flow was assessed with transit-time flowmetry in all patients and the peripheral anastomoses were assessed with epicardial ultrasound in 28 patients. Sixty-two patients underwent angiography after a mean of 185 ± 92 days. A total of 82 grafts were evaluated angiographically. Grafts with TIMI flow 2 and 3 were assessed as patent.
Results. At angiographic follow-up, the overall graft patency rate was 84% (31/37) in the control group and 93% (42/45) in the clopidogrel group (P value was not significant [ns]). Graft patency rates for left internal mammary artery (LIMA) grafts were 92% (23/25) versus 96% (28/29) (ns), and for saphenous vein grafts were 66% (7/11) versus 87% (14/16) (ns), respectively.
Conclusion. The observed trend toward higher patency rates in patients treated with clopidogrel did not reach statistical significance. Further larger studies are necessary to confirm these preliminary results.
Arsan S, Koray AK, Cisbir SC. 2004. Clopidogrel in coronary artery surgery. Eur J of Cardiothorac Surg 26:869-71.nChu MWA, Wilson SR, Novick RJ, Stitt LW, Quantz MA. 2004. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 78:1536-41.nClarke TA, Waskell LA. 2003. Clopidogrel is metabolized by human cytochrome P450 3A and inhibited by atorvastatin. Drug Metab Dispos 31:53-9.nD'Ancona G, Karamanouikan HC, Salerno TA, Schmid S, Bergsland J. 1999. Flow measurement in coronary surgery. Heart Surg Forum 2:121-4.nDavid JL, Limet R. 1999. Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients. Thromb Haemost 82:1417-21.nGrover FL, Johnson RR, Marshall G, Hammermeister KE. 1994. Impact of mammary grafts on coronary bypass operative mortality and morbidity. Department of Veterans Affairs Cardiac Surgeons. Ann Thorac Surg 57:559-68.nGurbuz AT, Zia AA, Vuran AC, Cui H, Aytac A. 2006. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. Eur J Cardiothorac Surg 29:90-5.nHaaverstad R, Vitale N, Tjomsland O, Tromsdal A, Torp H, Samstad SO. 2002. Intraoperative color Doppler ultrasound assessment of LIMA-to-LAD anastomoses in off-pump coronary artery bypasses grafting. Ann Thorac Surg 74:S1390-4.nKapetanakis EI, Medlam DA, Boyce SW, et al. 2005. Administration prior to coronary artery bypasses grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J 26:576-83.nKazaz H, Ustonsoy H, Celkan MA, Soydink S, Kayiran C, Bayar E. 2006. Midterm results of off-pump coronary artery bypass surgery in 136 patients: an angiographic control study. J Card Surg 21:6-10.nKim KB, Lim C, Lee C, et al. 2001. Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts. Ann Thorac Surg 72:S1033-7.nLau WC, Gurbel PA, Watkins PB, et al. 2004. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 9:166-71.nLev EI, Patel RT, Kelly J, et al. 2006. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47:27-33.nMishkel GJ, Aguirre FV, Ligon RW, Rocha-Singh KJ, Lucore CL. 1999. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 34:1884-90.nMuller I, Seyfarth M, Rudiger S, et al. 2001. Effects of a high dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92-3.nNeubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. 2003. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function—a flow cytometry study. Eur Heart J 24:1744-9.nOnorati F, De Feo M, Cerasuolo F, et al. 2005. Myocardial protection in diabetics with left main stem disease: which is the best strategy? J Cardiovasc Surg 46:305-12.nParolai A, Alemanni F, Polvani G, et al. 2005. Meta-analysis of randomized trials comparing off-pump with on-pump coronary artery bypass graft patency. Ann Thorac Surg 80:2121-5.nPuskas JD, Williams WH, Mahoney EM, et al. 2004. Off-Pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes. A randomized trial. JAMA 291:1841-9.nSavcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. 1999. Clopidogrel loading dose regimens kinetic profile of pharmaco-dynamic response in healthy subjects. Semin Thromb Hemost 25 (suppl 2):15-9.nThebault JJ, Kieffer G, Cariou R. 1999. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 25(suppl 2):3-8.nThe TIMI study group. 1984. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 33:523-30.nUnn KK, Kottke BA, Titus JL, Frye RL, Wallace RB, Brown AL. 1974. Pathologic changes in aortocoronary saphenous vein grafts. Am J Cardiol 34:526-32.nWong CK, French JK, Aylward P, et al. 2005. Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. J Am Coll Cardiol 46:29-38.nYusuf S, Phil D, Zhao F, et al. 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).